The T790M mutation is clinically significant because it accounts for approximately 50-60% of acquired resistance to EGFR TKIs in patients with NSCLC. Understanding the presence of this mutation can guide treatment strategies, leading to the use of third-generation TKIs like osimertinib, which are specifically designed to overcome T790M-mediated resistance.
